» Articles » PMID: 28400116

The Role of Infection in Interstitial Lung Diseases: A Review

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2017 Apr 13
PMID 28400116
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Interstitial lung disease (ILD) comprises an array of heterogeneous parenchymal lung diseases that are associated with a spectrum of pathologic, radiologic, and clinical manifestations. There are ILDs with known causes and those that are idiopathic, making treatment strategies challenging. Prognosis can vary according to the type of ILD, but many exhibit gradual progression with an unpredictable clinical course in individual patients, as seen in idiopathic pulmonary fibrosis and the phenomenon of "acute exacerbation"(AE). Given the often poor prognosis of these patients, the search for a reversible cause of respiratory worsening remains paramount. Infections have been theorized to play a role in ILDs, both in the pathogenesis of ILD and as potential triggers of AE. Research efforts thus far have shown the highest association with viral pathogens; however, fungal and bacterial organisms have also been implicated. This review aims to summarize the current knowledge on the role of infections in the setting of ILD.

Citing Articles

PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer.

Wang H, Chen K, Ma S, Huang W, Xie J, Wang N BMC Cancer. 2025; 25(1):263.

PMID: 39953451 PMC: 11827195. DOI: 10.1186/s12885-025-13673-4.


Outcome of COVID-19 in patients with idiopathic inflammatory myopathy during the Omicron wave in China: A longitudinal observational study.

Li Y, Tian X, Sun C, Wei Y, Jiang W, He L PLoS One. 2025; 20(2):e0317319.

PMID: 39928605 PMC: 11809795. DOI: 10.1371/journal.pone.0317319.


The Saudi thoracic society guidelines for vaccinations in adult patients with chronic respiratory diseases.

Al Ghobain M, Farahat F, Zeitouni M, Alsowayan W, Al-Awfi S, AlBarrak A Ann Thorac Med. 2025; 20(1):36-48.

PMID: 39926401 PMC: 11804953. DOI: 10.4103/atm.atm_202_24.


Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study.

Triboulet F, Juge P, Truchetet M, Pham T, Roux N, Flipo R RMD Open. 2025; 11(1.

PMID: 39762124 PMC: 11749054. DOI: 10.1136/rmdopen-2024-005062.


The Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation.

Zanini U, Faverio P, Bonfanti V, Falzone M, Cortinovis D, Arcangeli S J Clin Med. 2024; 13(23).

PMID: 39685543 PMC: 11641964. DOI: 10.3390/jcm13237085.


References
1.
Shulgina L, Cahn A, Chilvers E, Parfrey H, Clark A, Wilson E . Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2012; 68(2):155-62. DOI: 10.1136/thoraxjnl-2012-202403. View

2.
Drake W, Richmond B, Oswald-Richter K, Yu C, Isom J, Worrell J . Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30(3):201-11. PMC: 3929334. View

3.
Richter A, Stockley R, Harper L, Thickett D . Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax. 2009; 64(8):692-7. DOI: 10.1136/thx.2008.110445. View

4.
Vidal S, de la Horra C, Martin J, Montes-Cano M, Rodriguez E, Respaldiza N . Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect. 2006; 12(3):231-5. DOI: 10.1111/j.1469-0691.2005.01337.x. View

5.
Gupta D, Agarwal R, Aggarwal A, Jindal S . Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J. 2007; 30(3):508-16. DOI: 10.1183/09031936.00002607. View